The applying from Lykos — a drug organization incubated by the Multidisciplinary Affiliation for Psychedelic Scientific tests, or MAPS — arrived in the FDA below a cloud of controversy. Previous demo members experienced alleged adverse situations weren't reported — including inner thoughts of suicidality following the treatment — Which bias